Skip to content

Intellia Therapeutics

US · NTLA #2899 by market cap Listed 2016
10.00 +0.48 +5.04%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Founded
2014
CEO
Dr. John M. Leonard, M.D.
Employees
377
Headquarters
Cambridge, Massachusetts, United States of America
Fiscal year end
12-31
Website
intelliatx.com

Company profile

Exchange
US
Symbol
NTLA
Market-cap rank
#2899
Listing date
2016-05-06
Market cap
1.40B
Float cap
1.34B
Shares out
140.36M
Float shares
134.45M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.

Intellia Therapeutics discussion 0 comments

Add a comment